{"id":"divalproex-sodium-depakote","safety":{"commonSideEffects":[{"rate":"25-50%","effect":"Tremor"},{"rate":"20-40%","effect":"Nausea"},{"rate":"15-30%","effect":"Sedation/somnolence"},{"rate":"10-25%","effect":"Weight gain"},{"rate":"5-15%","effect":"Alopecia (hair loss)"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"1-3%","effect":"Hepatotoxicity"},{"rate":"<1%","effect":"Pancreatitis"}]},"_chembl":{"chemblId":"CHEMBL2105613","moleculeType":"Small molecule","molecularWeight":"310.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Divalproex is a compound of sodium valproate and valproic acid that works through multiple mechanisms: it increases brain levels of GABA (an inhibitory neurotransmitter) by inhibiting its degradation, blocks sodium channels to reduce neuronal excitability, and inhibits histone deacetylase enzymes which affects gene expression. These combined effects make it effective for conditions characterized by abnormal neuronal firing or mood dysregulation.","oneSentence":"Divalproex sodium inhibits histone deacetylase and enhances GABA neurotransmission, stabilizing neuronal membranes and reducing abnormal electrical activity in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:44.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (seizure disorders)"},{"name":"Bipolar disorder (acute mania)"},{"name":"Migraine prophylaxis"}]},"trialDetails":[{"nctId":"NCT07487675","phase":"PHASE2","title":"Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanta University","startDate":"2024-09-29","conditions":"Temporomandibular Joint Internal Derangement (ADWR)","enrollment":10},{"nctId":"NCT02068586","phase":"PHASE2","title":"Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2014-11-19","conditions":"Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma","enrollment":210},{"nctId":"NCT06714448","phase":"","title":"A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-04-29","conditions":"Epilepsy, Seizures","enrollment":3500},{"nctId":"NCT06081283","phase":"PHASE4","title":"Antiseizure Medication in Seizure Networks at Early Acute Brain Injury","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-11-20","conditions":"Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia","enrollment":5},{"nctId":"NCT07166393","phase":"PHASE2, PHASE3","title":"Valproic AcId for Traumatic BRAin INjury Trial","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-05","conditions":"Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury","enrollment":432},{"nctId":"NCT05694936","phase":"PHASE2","title":"Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2023-01-23","conditions":"Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT07046676","phase":"PHASE4","title":"Pharmacogenetics-Based Study on Individualized Use of Sodium Valproate","status":"RECRUITING","sponsor":"The First Affiliated Hospital of University of South China","startDate":"2022-12-01","conditions":"Epilepsy","enrollment":312},{"nctId":"NCT00306475","phase":"PHASE4","title":"Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2006-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":60},{"nctId":"NCT03919292","phase":"PHASE1, PHASE2","title":"Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2019-05-01","conditions":"Solid Tumor, Adult","enrollment":83},{"nctId":"NCT05722951","phase":"PHASE3","title":"Metformin Efficacy and Safety in Epileptic Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-18","conditions":"Epilepsy","enrollment":60},{"nctId":"NCT00211757","phase":"PHASE2","title":"Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2002-09","conditions":"Autism","enrollment":27},{"nctId":"NCT05224531","phase":"PHASE2","title":"Effect of CS1 in Subjects With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Cereno Scientific AB","startDate":"2022-05-05","conditions":"Pulmonary Arterial Hypertension","enrollment":25},{"nctId":"NCT03717909","phase":"PHASE2","title":"Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2018-12-28","conditions":"Wolfram Syndrome","enrollment":63},{"nctId":"NCT05881928","phase":"PHASE4","title":"Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-29","conditions":"Epilepsy, Lamotrigine, Sodium Valproate Adverse Reaction","enrollment":50},{"nctId":"NCT01817751","phase":"PHASE2","title":"Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2013-04-11","conditions":"Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma","enrollment":47},{"nctId":"NCT00145470","phase":"PHASE3","title":"12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-06-02","conditions":"Bipolar Disorder","enrollment":326},{"nctId":"NCT04698525","phase":"PHASE3","title":"Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2019-02-15","conditions":"Migraine Headache","enrollment":33},{"nctId":"NCT06393309","phase":"","title":"Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2022-09-03","conditions":"Treatment of Idiopathic Generalized Epilepsy","enrollment":169},{"nctId":"NCT05920512","phase":"PHASE1, PHASE2","title":"Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.","status":"UNKNOWN","sponsor":"Xue-chun Lu","startDate":"2022-04-01","conditions":"Hemophilia","enrollment":10},{"nctId":"NCT06020898","phase":"PHASE2","title":"Sodium Valproate in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-09-01","conditions":"Acute Ischemic Stroke","enrollment":40},{"nctId":"NCT00221429","phase":"PHASE3","title":"Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2001-03","conditions":"Bipolar Disorder","enrollment":153},{"nctId":"NCT06214130","phase":"PHASE1","title":"Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2023-09-22","conditions":"Multiple Drug Use","enrollment":22},{"nctId":"NCT06211283","phase":"PHASE1","title":"Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2023-09-11","conditions":"Food-drug Interaction","enrollment":28},{"nctId":"NCT04940572","phase":"PHASE2","title":"Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome","status":"UNKNOWN","sponsor":"Centre d'Etude des Cellules Souches","startDate":"2021-11-26","conditions":"Wolfram Syndrome","enrollment":23},{"nctId":"NCT03825250","phase":"PHASE1, PHASE2","title":"The Val-CARD Trial","status":"UNKNOWN","sponsor":"University of Leicester","startDate":"2018-11-06","conditions":"Cardiac Valve Disease, Coronary Artery Disease, Organ Failure, Multiple","enrollment":122},{"nctId":"NCT05641649","phase":"PHASE4","title":"Bioequivalence Study of Sodium Valproate and Valproic Acid Tablets","status":"UNKNOWN","sponsor":"Kathmandu University","startDate":"2023-08-06","conditions":"Epilepsy","enrollment":16},{"nctId":"NCT04997811","phase":"PHASE2","title":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Prof. Janet Dunn","startDate":"2021-12-21","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":120},{"nctId":"NCT05481957","phase":"PHASE4","title":"Vortioxetine Adjunctive Treatment in Bipolar Depression","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-03-01","conditions":"Bipolar Depression","enrollment":131},{"nctId":"NCT05017454","phase":"EARLY_PHASE1","title":"Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2021-05-01","conditions":"Alopecia Areata","enrollment":67},{"nctId":"NCT04513314","phase":"PHASE4","title":"Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2023-03-28","conditions":"Covid19, Hyperactive Delirium, Pneumonia, Viral","enrollment":""},{"nctId":"NCT02899611","phase":"PHASE1, PHASE2","title":"A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures","status":"COMPLETED","sponsor":"Cerebral Therapeutics LLC","startDate":"2016-08","conditions":"Epilepsy","enrollment":6},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05697614","phase":"PHASE4","title":"The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children","status":"UNKNOWN","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2023-03-01","conditions":"Drug Resistant Epilepsy","enrollment":100},{"nctId":"NCT03616223","phase":"PHASE1, PHASE2","title":"FX-322 in Sensorineural Hearing Loss","status":"COMPLETED","sponsor":"Frequency Therapeutics","startDate":"2018-07-03","conditions":"Sensorineural Hearing Loss","enrollment":23},{"nctId":"NCT03652974","phase":"PHASE4","title":"Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2018-09-06","conditions":"Schizophrenia","enrollment":145},{"nctId":"NCT03636958","phase":"NA","title":"Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy","status":"WITHDRAWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2021-02-15","conditions":"Refractory Epilepsy","enrollment":""},{"nctId":"NCT01730313","phase":"PHASE2","title":"Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-02","conditions":"Nodding Syndrome","enrollment":""},{"nctId":"NCT03681158","phase":"PHASE1","title":"Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-10-05","conditions":"Epilepsy","enrollment":5},{"nctId":"NCT03012815","phase":"PHASE4","title":"Gabapentin for Alcohol Withdrawal Syndrome","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-02-01","conditions":"Alcohol Withdrawal Syndrome","enrollment":88},{"nctId":"NCT03940326","phase":"PHASE4","title":"Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2018-04-01","conditions":"Epilepsy, Idiopathic Generalized","enrollment":103},{"nctId":"NCT00145509","phase":"PHASE3","title":"40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Bipolar Disorder","enrollment":77},{"nctId":"NCT04531592","phase":"PHASE2","title":"Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients","status":"WITHDRAWN","sponsor":"Westat","startDate":"2022-01","conditions":"Acute Kidney Injury, Ischemia Reperfusion Injury","enrollment":""},{"nctId":"NCT04531579","phase":"PHASE2","title":"Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients","status":"WITHDRAWN","sponsor":"Westat","startDate":"2022-01","conditions":"Acute Kidney Injury, Ischemia Reperfusion Injury","enrollment":""},{"nctId":"NCT01738815","phase":"EARLY_PHASE1","title":"Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2011-12","conditions":"Hematuria, Bladder Cancer","enrollment":43},{"nctId":"NCT04251234","phase":"NA","title":"Light at Night Study","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2020-10-15","conditions":"Bipolar Disorder, Light Sensitivity","enrollment":2},{"nctId":"NCT04902105","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2021-05-13","conditions":"Drug Interaction","enrollment":38},{"nctId":"NCT00879437","phase":"PHASE2","title":"Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-09-01","conditions":"Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme","enrollment":38},{"nctId":"NCT00078754","phase":"PHASE2","title":"A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2003-05","conditions":"Intermittent Explosive Disorder","enrollment":90},{"nctId":"NCT00312494","phase":"PHASE3","title":"3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-04","conditions":"Bipolar Disorder","enrollment":680},{"nctId":"NCT01588457","phase":"PHASE4","title":"Sequential Multiple Assignment Treatment for Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-06","conditions":"Bipolar I Disorder, Bipolar II Disorder","enrollment":112},{"nctId":"NCT04482764","phase":"PHASE1","title":"Valproic Acid in Treating Cyanotic Breath Holding Spells","status":"COMPLETED","sponsor":"Assiut University","startDate":"2017-01-30","conditions":"Breathhold","enrollment":150},{"nctId":"NCT00579280","phase":"PHASE4","title":"Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2007-07","conditions":"Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder","enrollment":224},{"nctId":"NCT01272531","phase":"","title":"Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-04","conditions":"Bipolar Affective Disorder","enrollment":560},{"nctId":"NCT02707965","phase":"PHASE1","title":"Characterization of Epilepsy Patients BEEP 2b","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-06-08","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT00356018","phase":"","title":"Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:","status":"COMPLETED","sponsor":"Orlando Health, Inc.","startDate":"2006-07","conditions":"Epilepsy","enrollment":5},{"nctId":"NCT04262999","phase":"","title":"Bone Mineral Density and Periodontal Status in Patients on Antiepileptic Drug","status":"UNKNOWN","sponsor":"Postgraduate Institute of Dental Sciences Rohtak","startDate":"2020-01-01","conditions":"Alveolar Bone Loss","enrollment":140},{"nctId":"NCT01760785","phase":"NA","title":"Valproate for Mood Swings and Alcohol Use Following Head Injury","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-09","conditions":"Traumatic Brain Injury (TBI), Alcoholism","enrollment":50},{"nctId":"NCT00397020","phase":"PHASE4","title":"Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-12","conditions":"Bipolar Disorder","enrollment":30},{"nctId":"NCT00194116","phase":"PHASE3","title":"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-09","conditions":"Bipolar Disorder","enrollment":54},{"nctId":"NCT03914534","phase":"PHASE4","title":"Bioequivalence Study of Sodium Divalproate Tablets 500 mg","status":"COMPLETED","sponsor":"Tecnoquimicas","startDate":"2017-04-17","conditions":"Healthy","enrollment":30},{"nctId":"NCT03903302","phase":"PHASE1","title":"Study Investigation Pharmacokinetics and Pharmacodynamics of CS1","status":"COMPLETED","sponsor":"Cereno Scientific AB","startDate":"2017-10-06","conditions":"Thrombosis","enrollment":30},{"nctId":"NCT02926976","phase":"NA","title":"The Optimal Treatment for Treatment-resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2016-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT01928849","phase":"PHASE2","title":"Valproic Acid for the Prevention of Post-Amputation Pain","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-12","conditions":"Pain, Phantom, Pain, Neuropathic","enrollment":128},{"nctId":"NCT01791868","phase":"NA","title":"Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-02","conditions":"Generalized Convulsive Status Epilepticus, Intensive Care Unit","enrollment":245},{"nctId":"NCT00254488","phase":"PHASE4","title":"Treatment of Bipolar Mania in Older Adults","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2005-11","conditions":"Bipolar Disorder, Mania","enrollment":224},{"nctId":"NCT00183443","phase":"PHASE3","title":"Treatment of Mania Symptoms With Drug Therapy","status":"COMPLETED","sponsor":"Palo Alto Veterans Institute for Research","startDate":"2005-02","conditions":"Bipolar Disorder, Schizophrenia","enrollment":75},{"nctId":"NCT00211796","phase":"PHASE4","title":"Divalproex Sodium ER in Adult Autism","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2005-04","conditions":"Autism","enrollment":10},{"nctId":"NCT01182285","phase":"PHASE2","title":"A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-24","conditions":"Thyroid Neoplasm","enrollment":13},{"nctId":"NCT00194129","phase":"PHASE3","title":"Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"1997-11","conditions":"Bipolar Disorder","enrollment":31},{"nctId":"NCT02011750","phase":"PHASE4","title":"Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-04-01","conditions":"Toxoplasmosis, Schizophrenia","enrollment":109},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283},{"nctId":"NCT02413918","phase":"PHASE4","title":"Iloperidone in Mixed States of Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2012-04","conditions":"Bipolar Disorder","enrollment":41},{"nctId":"NCT03112889","phase":"PHASE2","title":"Sodium Valproate for GSDV","status":"COMPLETED","sponsor":"University College, London","startDate":"2015-01","conditions":"Glycogen Storage Disease Type V, McArdle Disease","enrollment":8},{"nctId":"NCT00318929","phase":"NA","title":"Tolerability and Efficacy of Depakote-extended Release in the Elderly","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2006-04","conditions":"Elderly, Epilepsy, Seizures","enrollment":14},{"nctId":"NCT02608736","phase":"EARLY_PHASE1","title":"Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2015-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT00000439","phase":"PHASE2","title":"Drug Treatment for Alcoholics With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2000-10","conditions":"Alcoholism, Bipolar Disorder","enrollment":72},{"nctId":"NCT00665444","phase":"NA","title":"Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2008-04","conditions":"Bipolar Disorder, Metabolic Syndrome","enrollment":3},{"nctId":"NCT00218114","phase":"PHASE3","title":"Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2000-02","conditions":"Attention Deficit and Disruptive Behavior Disorders, Marijuana Abuse","enrollment":25},{"nctId":"NCT01170325","phase":"PHASE2","title":"A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG","status":"WITHDRAWN","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2010-06-30","conditions":"Autism, Autism Spectrum Disorders","enrollment":""},{"nctId":"NCT00609245","phase":"PHASE4","title":"Effect of Valproic Acid Concentration on Photic Response","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2007-12","conditions":"Photosensitive Epilepsy","enrollment":13},{"nctId":"NCT02648633","phase":"PHASE1","title":"Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2016-05-24","conditions":"Glioblastoma","enrollment":4},{"nctId":"NCT00183469","phase":"PHASE4","title":"Maintenance Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2004-12","conditions":"Bipolar Disorder, Depression","enrollment":86},{"nctId":"NCT00223496","phase":"PHASE4","title":"12- Week Open Label Treatment of Refractory Bipolar Depression","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2004-09","conditions":"Bipolar Disorder","enrollment":32},{"nctId":"NCT02205931","phase":"PHASE4","title":"Ketogenic Diet in Infants With Epilepsy (KIWE)","status":"UNKNOWN","sponsor":"University College, London","startDate":"2015-01","conditions":"Epilepsy","enrollment":160},{"nctId":"NCT00315900","phase":"PHASE3","title":"Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia","status":"TERMINATED","sponsor":"Tuscaloosa Research & Education Advancement Corporation","startDate":"2006-05-01","conditions":"Agitation, Dementia","enrollment":20},{"nctId":"NCT00451542","phase":"","title":"Divalproex vs. Lamotrigine for Bipolar Disorder","status":"TERMINATED","sponsor":"Tuscaloosa Research & Education Advancement Corporation","startDate":"2006-02-01","conditions":"Bipolar Disorder","enrollment":1000},{"nctId":"NCT00203385","phase":"PHASE4","title":"Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder","status":"TERMINATED","sponsor":"Tuscaloosa Research & Education Advancement Corporation","startDate":"2003-05","conditions":"PTSD","enrollment":20},{"nctId":"NCT00864006","phase":"PHASE1","title":"Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2006-10","conditions":"Seizures","enrollment":28},{"nctId":"NCT00913848","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-10","conditions":"Epilepsy, Bipolar Disorder","enrollment":30},{"nctId":"NCT00913874","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-10","conditions":"Epilepsy, Bipolar Disorder","enrollment":30},{"nctId":"NCT00217932","phase":"PHASE2","title":"Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2000-09","conditions":"Mood Disorders","enrollment":15},{"nctId":"NCT02078596","phase":"PHASE4","title":"Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"1997-03","conditions":"Irritable Aggression","enrollment":15},{"nctId":"NCT00063362","phase":"PHASE3","title":"Combination Therapy for the Treatment of Bipolar Disorders","status":"TERMINATED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2002-02","conditions":"Bipolar Disorder","enrollment":49},{"nctId":"NCT02094651","phase":"PHASE2","title":"Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium","status":"WITHDRAWN","sponsor":"Boston Children's Hospital","startDate":"2014-04","conditions":"Autism","enrollment":""},{"nctId":"NCT00240110","phase":"PHASE1, PHASE2","title":"Valproate Efficacy in Cocaine-Bipolar Comorbidity","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-03","conditions":"Bipolar Disorder, Cocaine Dependence","enrollment":152},{"nctId":"NCT02920060","phase":"PHASE2","title":"Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2015-01","conditions":"Grand Mal Status Epilepticus","enrollment":80},{"nctId":"NCT01358357","phase":"PHASE3","title":"Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-06","conditions":"Bipolar I Disorder","enrollment":965},{"nctId":"NCT01575561","phase":"PHASE3","title":"This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-06","conditions":"Bipolar I Disorder","enrollment":377},{"nctId":"NCT02166229","phase":"PHASE1, PHASE2","title":"Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2014-06","conditions":"Scleroderma, Systemic Sclerosis","enrollment":""},{"nctId":"NCT01342549","phase":"PHASE3","title":"Treatment Strategy for Alcohol Use Disorders in Veterans With TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-09","conditions":"Alcohol Dependence","enrollment":62}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"DECUBITUS ULCER"},{"count":1,"reaction":"DIABETES MELLITUS INADEQUATE CONTROL"},{"count":1,"reaction":"DRUG LEVEL ABOVE THERAPEUTIC"},{"count":1,"reaction":"DYSKINESIA"},{"count":1,"reaction":"GASTROINTESTINAL HAEMORRHAGE"},{"count":1,"reaction":"INFECTION"},{"count":1,"reaction":"INFLUENZA LIKE ILLNESS"},{"count":1,"reaction":"MYOCARDITIS"},{"count":1,"reaction":"OVERDOSE"}],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Divalproex Sodium (Depakote)","genericName":"Divalproex Sodium (Depakote)","companyName":"National Institute on Drug Abuse (NIDA)","companyId":"national-institute-on-drug-abuse-nida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Divalproex sodium inhibits histone deacetylase and enhances GABA neurotransmission, stabilizing neuronal membranes and reducing abnormal electrical activity in the brain. Used for Epilepsy (seizure disorders), Bipolar disorder (acute mania), Migraine prophylaxis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}